TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

BAUSCH

DermatologyImmunologyOphthalmology
Specialty

BAUSCH is a specialty pharmaceutical company focused on Dermatology, Immunology, Ophthalmology. Key products include LUZU.

1946
Since
84
Drugs
-
Trials
190
Approved (2yr)

Key Drugs

LUZU
luliconazole
3 indications · 2013
DUOBRII
halobetasol propionate
Immunology
RARα 1 indications · 2019
BRYHALI
halobetasol propionate
Immunology
1 indications · 2018
JUBLIA
efinaconazole
1 indications · 2014
ARAZLO
tazarotene
RARα 1 indications · 2019

Recent Activity

IPRATROPIUM BROMIDE 2026-02-23
DOXYCYCLINE HYCLATE 2026-02-19
DOXYCYCLINE HYCLATE 2026-02-06
Labeling
DOXYCYCLINE HYCLATE 2026-02-06
Labeling
DOXYCYCLINE HYCLATE 2026-01-26
Labeling
FENOFIBRATE 2026-01-21
DOXYCYCLINE HYCLATE 2026-01-20
Labeling
DOXYCYCLINE HYCLATE 2026-01-20
Labeling
DOXYCYCLINE HYCLATE 2026-01-18
Labeling
DOXYCYCLINE HYCLATE 2025-12-09
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Dermatology 40%
11 drugs Phase 3: 10 Phase 2: 4 Phase 1: 3
Immunology 22%
5 drugs Phase 3: 5 Phase 2: 4 Phase 1: 7
Ophthalmology 14%
0 drugs Phase 3: 7 Phase 2: 2 Phase 1: 10
Cardiovascular 13%
6 drugs Phase 1: 3
Gastroenterology 10%
2 drugs Phase 3: 2 Phase 2: 2 Phase 1: 4

Pipeline Strength Pro

Loading...

Competitors Pro

Pfizer big-pharma
Dermatology, Immunology, Gastroenterology
Novartis big-pharma
Cardiovascular, Immunology, Ophthalmology
BAUSCH AND LOMB specialty
Ophthalmology, Cardiovascular, Dermatology, Immunology
Baxter specialty
Cardiovascular, Dermatology, Ophthalmology
Bayer big-pharma
Cardiovascular, Ophthalmology, Dermatology